Total Payments
$1,665
2024 Payments
$83.55
Companies
13
Transactions
47
Medicare Patients
1,825
Medicare Billing
$93,078
Payment Breakdown by Category
Food & Beverage$965.37 (58.0%)
Consulting$700.00 (42.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $965.37 | 46 | 58.0% |
| Consulting Fee | $700.00 | 1 | 42.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Aurobindo Pharma USA, Inc. | $700.00 | 1 | $0 (2020) |
| Amgen Inc. | $215.81 | 12 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $178.39 | 5 | $0 (2020) |
| Sun Pharmaceutical Industries Inc. | $128.96 | 9 | $0 (2020) |
| MAYNE PHARMA INC. | $126.83 | 7 | $0 (2020) |
| Helsinn Therapeutics (U.S.), Inc. | $109.04 | 1 | $0 (2018) |
| Organogenesis Inc. | $57.56 | 2 | $0 (2024) |
| Allergan Inc. | $39.78 | 3 | $0 (2017) |
| PFIZER INC. | $34.68 | 2 | $0 (2022) |
| Incyte Corporation | $25.99 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $83.55 | 3 | Organogenesis Inc. ($57.56) |
| 2023 | $27.86 | 1 | Amgen Inc. ($27.86) |
| 2022 | $34.68 | 2 | PFIZER INC. ($34.68) |
| 2020 | $880.97 | 11 | Aurobindo Pharma USA, Inc. ($700.00) |
| 2019 | $191.93 | 13 | Sun Pharmaceutical Industries Inc. ($53.84) |
| 2018 | $278.59 | 6 | Helsinn Therapeutics (U.S.), Inc. ($109.04) |
| 2017 | $167.79 | 11 | Amgen Inc. ($58.78) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $25.99 | General |
| Category: Dermatology | ||||||
| 08/27/2024 | Organogenesis Inc. | — | Food and Beverage | In-kind items and services | $26.98 | General |
| 07/01/2024 | Organogenesis Inc. | — | Food and Beverage | In-kind items and services | $30.58 | General |
| 06/28/2023 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: Inflammation | ||||||
| 12/15/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: DERMATOLOGY | ||||||
| 08/30/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: DERMATOLOGY | ||||||
| 10/14/2020 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Inflammation | ||||||
| 07/10/2020 | Aurobindo Pharma USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 07/08/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $14.92 | General |
| Category: Dermatology | ||||||
| 06/29/2020 | MAYNE PHARMA INC. | DORYX (Drug) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: DERMATOLOGY | ||||||
| 06/11/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| Category: Dermatology | ||||||
| 02/27/2020 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $18.55 | General |
| 02/19/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $17.05 | General |
| Category: Dermatology | ||||||
| 02/04/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Inflammation | ||||||
| 01/16/2020 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.23 | General |
| 01/08/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $13.48 | General |
| Category: Dermatology | ||||||
| 01/06/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Inflammation | ||||||
| 10/28/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $16.77 | General |
| 10/16/2019 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $13.62 | General |
| Category: Dermatology | ||||||
| 08/01/2019 | Mayne Pharma Inc. | DORYX (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: DERMATOLOGY | ||||||
| 06/19/2019 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $14.83 | General |
| Category: Dermatology | ||||||
| 05/28/2019 | Genentech USA, Inc. | Erivedge (Biological) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: BioOncology | ||||||
| 05/13/2019 | Mayne Pharma Inc. | DORYX (Drug) | Food and Beverage | In-kind items and services | $13.06 | General |
| Category: DERMATOLOGY | ||||||
| 04/29/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $15.18 | General |
| 04/11/2019 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $12.79 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 492 | 723 | $148,968 | $25,565 |
| 2022 | 10 | 474 | 760 | $133,400 | $23,263 |
| 2021 | 11 | 479 | 841 | $131,521 | $26,048 |
| 2020 | 8 | 380 | 659 | $105,344 | $18,202 |
Total Patients
1,825
Total Services
2,983
Medicare Billing
$93,078
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 102 | 140 | $36,260 | $9,169 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 128 | 149 | $26,671 | $6,669 | 25.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 61 | 75 | $17,400 | $2,479 | 14.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 24 | 24 | $8,688 | $2,074 | 23.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2023 | 34 | 37 | $10,989 | $1,623 | 14.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Facility | 2023 | 12 | 14 | $7,028 | $1,030 | 14.7% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2023 | 47 | 51 | $19,839 | $1,003 | 5.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 12 | 12 | $2,664 | $560.97 | 21.1% |
| 11104 | Punch biopsy, first skin growth | Facility | 2023 | 13 | 13 | $6,266 | $452.74 | 7.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2023 | 48 | 197 | $11,623 | $290.40 | 2.5% |
| 11900 | Injection into skin growth, 1-7 growths | Facility | 2023 | 11 | 11 | $1,540 | $213.75 | 13.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 113 | 138 | $33,726 | $8,579 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 107 | 126 | $21,482 | $5,607 | 26.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 67 | 86 | $18,839 | $2,919 | 15.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 29 | 29 | $9,937 | $2,831 | 28.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2022 | 24 | 25 | $7,074 | $945.88 | 13.4% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2022 | 39 | 47 | $18,121 | $842.14 | 4.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 19 | 20 | $2,090 | $516.61 | 24.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Facility | 2022 | 14 | 28 | $5,796 | $430.35 | 7.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2022 | 50 | 248 | $14,632 | $368.34 | 2.5% |
| 11900 | Injection into skin growth, 1-7 growths | Facility | 2022 | 12 | 13 | $1,703 | $223.24 | 13.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 118 | 166 | $35,362 | $11,431 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 74 | 89 | $14,155 | $4,208 | 29.7% |
| 17000 | Destruction of skin growth | Facility | 2021 | 78 | 100 | $21,100 | $3,550 | 16.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 33 | 33 | $10,737 | $3,259 | 30.4% |
About Dr. John Maize, MD
Dr. John Maize, MD is a Dermatopathology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982683611.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Maize, MD has received a total of $1,665 in payments from pharmaceutical and medical device companies, with $83.55 received in 2024. These payments were reported across 47 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($965.37).
As a Medicare-enrolled provider, Maize has provided services to 1,825 Medicare beneficiaries, totaling 2,983 services with total Medicare billing of $93,078. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatopathology
- Location Charleston, SC
- Active Since 01/11/2006
- Last Updated 11/05/2020
- Taxonomy Code 207ND0900X
- Entity Type Individual
- NPI Number 1982683611
Products in Payments
- Enbrel (Biological) $176.03
- DORYX (Drug) $126.83
- ILUMYA (Biological) $113.29
- VALCHLOR (Drug) $109.04
- COSENTYX (Biological) $105.66
- Otezla (Drug) $39.78
- EUCRISA (Drug) $34.68
- OPZELURA (Drug) $25.99
- ACZONE (Drug) $25.68
- Erivedge (Biological) $16.23
- ILUMYA (tildrakizumab-asmn) injection (Biological) $15.67
- DALVANCE (Drug) $14.10
- REMICADE (Biological) $13.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatopathology Doctors in Charleston
Marta Hampton, Md, MD
Dermatopathology — Payments: $48,272
Dermatopathology $48,272
Dr. John Maize, Md, MD
Dermatopathology — Payments: $11,763
Dermatopathology $11,763
David Perry, M.d, M.D
Dermatopathology — Payments: $3,787
Dermatopathology $3,787
Dr. Graciela De Jesus, Md, MD
Dermatopathology
Dermatopathology